DCT and neoplasm: Two models were utilized, one with a xenogeneic model tumor antigen, OVA (the E.G7-OVA thymoma model; Fig. 3 and 4), where the antigen is not centrally tolerized, and one with an endogenous tumor antigen TRP-2 (B16-F10 melanoma; Fig. 5), in which central tolerance must be overcome.